Literature DB >> 30443695

Non-alcoholic fatty liver disease and colorectal cancer survival.

Kana Wu1, Mike Z Zhai2, Erin K Weltzien3, Elizabeth M Cespedes Feliciano3, Jeffrey A Meyerhardt4, Edward Giovannucci5,6, Bette J Caan3.   

Abstract

PURPOSE: Liver diseases including non-alcoholic fatty liver disease (NAFLD) and ensuing alterations to the micro-environment may affect development of liver metastasis. Mirroring the rise in obesity rates, prevalence of NAFLD is increasing globally. Our objective was to examine the association between NAFLD and mortality in colorectal cancer patients.
METHODS: Colorectal Cancer-Sarcopenia and Near-term Survival (C-SCANS) is a retrospective cohort study which included 3,262 stage I-III patients, aged 18-80 years, and diagnosed between 2006 and 2011 at Kaiser Permanente Northern California. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI).
RESULTS: After up to 10 years of follow-up, 879 deaths, including 451 from CRC were identified. Cases diagnosed with NAFLD before and within 1 month after CRC diagnosis (pre-existing NAFLD; n = 83) had a HR of 1.64 (95% CI 1.06-2.54) for overall and a HR of 1.85 (95% CI 1.03-3.30) for CRC-specific mortality compared to those without NAFLD. Findings did not differ significantly by sex, stage, tumor location, and smoking status, and were also similar when restricted to obese patients only.
CONCLUSIONS: Independent of body mass index and prognostic indicators, CRC patients with pre-existing NAFLD had a worse prognosis than those without NAFLD.

Entities:  

Keywords:  Colorectal cancer survival; Liver metastasis; Non-alcoholic fatty liver disease

Mesh:

Year:  2018        PMID: 30443695      PMCID: PMC6613648          DOI: 10.1007/s10552-018-1095-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  16 in total

1.  The rare occurrence of metastatic carcinoma in the cirrhotic liver.

Authors:  M M LIEBER
Journal:  Am J Med Sci       Date:  1957-02       Impact factor: 2.378

Review 2.  Chemoradiotherapy for colorectal cancer.

Authors:  N Andre; W Schmiegel
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

Review 3.  The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

4.  Influence of non-alcoholic fatty liver disease on the prognosis in patients with colorectal cancer.

Authors:  Yang Won Min; Hwan Sic Yun; Woo Ik Chang; Jin Yong Kim; Young-Ho Kim; Hee Jung Son; Jae J Kim; Jong Chul Rhee; Dong Kyung Chang
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-11-30       Impact factor: 2.947

5.  Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer.

Authors:  Koji Murono; Joji Kitayama; Nelson H Tsuno; Hiroaki Nozawa; Kazushige Kawai; Eiji Sunami; Masaaki Akahane; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2013-02-08       Impact factor: 2.571

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

7.  Global patterns and trends in colorectal cancer incidence and mortality.

Authors:  Melina Arnold; Mónica S Sierra; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  Gut       Date:  2016-01-27       Impact factor: 23.059

8.  High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.

Authors:  Michael Nathan VanSaun; In Kyu Lee; Mary Kay Washington; Lynn Matrisian; David Lee Gorden
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

9.  Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis.

Authors:  Jie You; Sha Huang; Gui-Qian Huang; Gui-Qi Zhu; Rui-Min Ma; Wen-Yue Liu; Ke-Qing Shi; Gui-Long Guo; Yong-Ping Chen; Martin Braddock; Ming-Hua Zheng
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

10.  Patients with chronically diseased livers have lower incidence of colorectal liver metastases: a meta-analysis.

Authors:  Bin Cai; Kai Liao; Xian-qing Song; Wei-yuan Wei; Yuan Zhuang; Sen Zhang
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

View more
  5 in total

Review 1.  Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links.

Authors:  Debrup Chakraborty; Jing Wang
Journal:  Life Sci       Date:  2020-10-02       Impact factor: 5.037

3.  Fat Quantification in Dual-Layer Detector Spectral Computed Tomography: Experimental Development and First In-Patient Validation.

Authors:  Isabel Molwitz; Graeme Michael Campbell; Jin Yamamura; Tobias Knopp; Klaus Toedter; Roland Fischer; Zhiyue Jerry Wang; Alina Busch; Ann-Kathrin Ozga; Shuo Zhang; Thomas Lindner; Florian Sevecke; Mirco Grosser; Gerhard Adam; Patryk Szwargulski
Journal:  Invest Radiol       Date:  2022-02-11       Impact factor: 10.065

4.  Liver imaging features by convolutional neural network to predict the metachronous liver metastasis in stage I-III colorectal cancer patients based on preoperative abdominal CT scan.

Authors:  Sangwoo Lee; Eun Kyung Choe; So Yeon Kim; Hua Sun Kim; Kyu Joo Park; Dokyoon Kim
Journal:  BMC Bioinformatics       Date:  2020-09-17       Impact factor: 3.169

5.  Biodistribution and Activity of EGFR Targeted Polymeric Micelles Delivering a New Inhibitor of DNA Repair to Orthotopic Colorectal Cancer Xenografts with Metastasis.

Authors:  Igor Moura de Paiva; Mohammad Reza Vakili; Amir Hasan Soleimani; Seyed Amirhossein Tabatabaei Dakhili; Sirazum Munira; Marco Paladino; Gary Martin; Frank R Jirik; Dennis G Hall; Michael Weinfeld; Afsaneh Lavasanifar
Journal:  Mol Pharm       Date:  2022-03-10       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.